Our ability to deliver drug candidates with defined clinical development path brings unparalleled value and efficiency for our strategic patners. Currently we are working with multiple major pharmaceutical companies to discover both small and large molecule therapeutics for cancer indications.
- Pfizer and Crown Bioscience established a joint Asian Cancer Research Center in 2009 to discover new drugs targeting cancer types prevalent in Asia
- Yangzi River Pharma Group, the largest pharmaceutical company in China, entered into an exclusive relationship wtih Crown Bioscience in 2010 to discover novel best-in-class molecule for a an undisclosed target
- A major global pharmaceutical company entered into a strategic partnership with Crown in 2011 to discover novel small molecule drug candidates
We are actively seeking additional partnership in the field of oncology and metabolic disease, please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it if you are interested to know more about our capability and explore how we can work together.